GlobeNewsWire
08 Jul 2026, 11:35 UTC · 3h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
Conavi Medical's next-generation hybrid IVUS-OCT imaging system received U.S. FDA 510(k) clearance in April 2026. — FDA clearance is the primary regulatory hurdle for commercialization and revenue generation in the US medical device market.
+0.60A new publication in JSCAI demonstrates that Conavi's hybrid system enables reduced contrast exposure, specifically benefiting patients with impaired renal function. — Clinical validation of a specific high-need use case (chronic kidney disease) supports broader physician adoption and market penetration.
+0.30The company is currently transitioning from regulatory approval to the active commercial rollout of its hybrid imaging system. — Moving into the commercial phase shifts the company's risk profile from regulatory/R&D risk to execution and sales risk.
+0.20Which stocks this story touches
Continue reading
6 related stories
Top 1 mover · tap to explore
The company announced a clinical publication demonstrating the utility and practical value of its hybrid imaging system following FDA clearance.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
GlobeNewsWire
56m ago
